Cargando…

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors

The urokinase-type plasminogen activator receptor (uPAR) is a GPI-anchored cell membrane receptor that focuses urokinase (uPA) proteolytic activity on the cell surface. Its expression is increased in many human cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mauro, Concetta Di, Pesapane, Ada, Formisano, Luigi, Rosa, Roberta, D’Amato, Valentina, Ciciola, Paola, Servetto, Alberto, Marciano, Roberta, Orsini, Roberta Clara, Monteleone, Francesca, Zambrano, Nicola, Fontanini, Gabriella, Servadio, Adele, Pignataro, Giuseppe, Grumetto, Lucia, Lavecchia, Antonio, Bruzzese, Dario, Iaccarino, Antonino, Troncone, Giancarlo, Veneziani, Bianca Maria, Montuori, Nunzia, Placido, Sabino De, Bianco, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571185/ https://www.ncbi.nlm.nih.gov/pubmed/28839232 http://dx.doi.org/10.1038/s41598-017-10062-1

Ejemplares similares

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
por: Raimondo, Lucia, et al.
Publicado: (2016)

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
por: Formisano, Luigi, et al.
Publicado: (2015)

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
por: Di Mauro, Concetta, et al.
Publicado: (2017)

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
por: Formisano, Luigi, et al.
Publicado: (2014)

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
por: Rosa, Roberta, et al.
Publicado: (2013)

Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion
por: Pesapane, Ada, et al.
Publicado: (2015)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor
por: Napolitano, Filomena, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

New Pieces in the Puzzle of uPAR Role in Cell Migration Mechanisms
por: Gorrasi, Anna, et al.
Publicado: (2020)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment
por: Selleri, Carmine, et al.
Publicado: (2016)

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
por: Belli, Stefania, et al.
Publicado: (2023)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
por: Shmakova, Anna A., et al.
Publicado: (2022)

The Urokinase/Urokinase Receptor System in Mast Cells: Effects of its Functional Interaction with fMLF Receptors
por: Rossi, Francesca Wanda, et al.
Publicado: (2016)

The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications
por: Li Santi, Anna, et al.
Publicado: (2021)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma
por: Semina, Ekaterina V., et al.
Publicado: (2020)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report
por: Marciano, Roberta, et al.
Publicado: (2017)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
por: Sharma, Shailza, et al.
Publicado: (2021)

The 37/67kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67kDa LR cell surface localization and interaction with the cellular prion protein
por: Sarnataro, Daniela, et al.
Publicado: (2016)

A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs
por: Li Santi, Anna, et al.
Publicado: (2018)

The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells
por: Lejeune, Danielle, et al.
Publicado: (2006)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells
por: Alfano, Daniela, et al.
Publicado: (2015)

c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
por: Belli, Stefania, et al.
Publicado: (2020)

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
por: Napolitano, Fabiana, et al.
Publicado: (2019)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
por: Servetto, Alberto, et al.
Publicado: (2021)

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
por: Harel, Efrat T., et al.
Publicado: (2019)

The Urokinase Receptor Takes Control of Cell Migration by Recruiting Integrins and FPR1 on the Cell Surface
por: Gorrasi, Anna, et al.
Publicado: (2014)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review
por: Manzo, Paola, et al.
Publicado: (2023)

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
por: Margheri, Francesca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1rbm1kb8qt7pttnj4kpc0jt6m1